| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/31/2002 | WO2002007516A2 Uses for nad synthetase inhibitors |
| 01/31/2002 | WO2001078580A3 A method combining inducing hypothermia and administering a therapeutic agent |
| 01/31/2002 | WO2001068146A3 Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene |
| 01/31/2002 | WO2001068120A3 Uses of bombesin receptor 3 |
| 01/31/2002 | WO2001064185A3 Method for making, loading and sealing a cell or drug encapsulation device, and such a device |
| 01/31/2002 | WO2001062341A3 Combination product for the treatment of obesity |
| 01/31/2002 | WO2001061017A3 Modified cytokines for use in cancer therapy |
| 01/31/2002 | WO2001060348A3 Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure |
| 01/31/2002 | WO2001054677A3 Ace inhibitor-vasopressin antagonist combinations |
| 01/31/2002 | WO2001039788A3 Methods for targeting cells that express fibroblast growth receptor-3 or-2 |
| 01/31/2002 | WO2001036605A3 2786, a human aminopeptidase |
| 01/31/2002 | WO2001034177A3 Method of treating a viral infection using antagonists of macrophage colony stimulating factor |
| 01/31/2002 | WO2000047219A3 Methods and reagents for treating glucose metabolic disorders |
| 01/31/2002 | US20020013484 Water solubility; prodrug containing polyether oligomer |
| 01/31/2002 | US20020013478 Viricides |
| 01/31/2002 | US20020013374 Administering compound effective to inhibit binding of an amyloid beta peptide with alpha-7 nicotinic acetylcholine receptors |
| 01/31/2002 | US20020013372 Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors |
| 01/31/2002 | US20020013366 Methods of treating tardive dyskinesia and other movement disorders |
| 01/31/2002 | US20020013364 Glycine site full agonist for treating a psychosis |
| 01/31/2002 | US20020013361 Treatment of rosacea using lipoic acid |
| 01/31/2002 | US20020013357 Valdecoxib compositions |
| 01/31/2002 | US20020013353 Blocking of associated non-inactivating sodium channels in retinal ganglion cells in order to limit sodium/calcium exchange in retinal ganglion cells and prevent buildup of calcium level in retinal ganglion cells to a lethal level |
| 01/31/2002 | US20020013352 Novel substituted diamine derivatives useful as motilin antagonists |
| 01/31/2002 | US20020013349 Administering drug which opens potassium channel for reducing pain |
| 01/31/2002 | US20020013347 Tri-aryl-substituted-ethane PDE4 inhibitors |
| 01/31/2002 | US20020013345 Treatment of diseases of the eye characterized by the formation of metalloproteinase |
| 01/31/2002 | US20020013335 Method of treating cardiovascular disease |
| 01/31/2002 | US20020013334 HMG-CoA reductase inhibitors and method |
| 01/31/2002 | US20020013331 For therapy of pain associated with mucosal damage, such as inflamation, abrasions, ulcerations, lesions, incisions, and trauma |
| 01/31/2002 | US20020013327 Administering estrogen agonist/antagonist, and optionally, co-administering an effective amount of a cyclic guanosine 3',5'-monophosphate elevator for therapy of female sexual dysfunction |
| 01/31/2002 | US20020013322 Novel compounds for enhancing chemotherapy |
| 01/31/2002 | US20020013320 Use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease |
| 01/31/2002 | US20020013312 Antidepressant effect of norepinephrine uptake 2 inhibitors and combined medications including them |
| 01/31/2002 | US20020013310 Inhibitors of the activity of Factor Xa such as 3-((1-(4-Aminoquinolin-7-ylmethyl)-2-oxopyrrolidin-3-(R)-yl)-( 5- chloro-1H-indol-2-ylmethyl)amino)propionic acid methyl ester |
| 01/31/2002 | US20020013308 Comprising insulin resistance improving agents in combination with drugs selected from angiotensin II receptor antagonists and angiotensin converting enzyme inhibitors with a diluent or carrier |
| 01/31/2002 | US20020013307 Administering compounds such as omapatrilat or gemopatrilat |
| 01/31/2002 | US20020013304 As needed rather than involving chronic pharmacotherapy; formulations and kits |
| 01/31/2002 | US20020013301 In an oral dosage form, providing a combination product analgesically effective when administered orally, but which is aversive in addicts at the same dose or higher dose than prescribed; prevention of drug abuse, drug dependency |
| 01/31/2002 | US20020013300 Methods for improving size and appearance of a wound |
| 01/31/2002 | US20020013296 Treating with agonists at kappa opioid receptors such as methyl-4-(2-glycyl-4-(trifluoromethylphenyl)acetyl)-3-(R,S)-((1 -pyrrolidinyl)-methyl)-1-piperazinecarboxylate |
| 01/31/2002 | US20020013288 Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
| 01/31/2002 | US20020013279 Hematopoietic stimulation |
| 01/31/2002 | US20020013268 Synergistic effect of a sulfonylurea and/or non-sulfonylurea Kchannel blocker, and a phosphodiesterase 3 type inhibitor |
| 01/31/2002 | US20020013263 Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
| 01/31/2002 | US20020013259 Therapeutic and diagnostic methods for ulcerative colitis and associated disorders |
| 01/31/2002 | US20020013257 Use of ligands to GABAB receptors |
| 01/31/2002 | US20020012992 Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor |
| 01/31/2002 | US20020012931 High specificity marker detection |
| 01/31/2002 | US20020012906 Method for kidney disease treatment by drug intervention |
| 01/31/2002 | US20020012709 Process and composition for controlling fecal hair excretion and trichobezoar formation |
| 01/31/2002 | US20020012708 For preparation of medicaments for treatment of organ and tissue damages caused by radiation, infections, and chemically, especially of O-MALT system of small intestine, bone marrow, spleen, lymph nodes, liver |
| 01/31/2002 | US20020012703 Treatment of oncologic tumors with an injectable formulation of a golgi apparatus disturbing agent |
| 01/31/2002 | US20020012689 For managing bowel regularity, hemorrhoids |
| 01/31/2002 | US20020012676 For inhibiting gastric acid secretion in mammals and man |
| 01/31/2002 | US20020012667 Method for preventing allograft rejection |
| 01/31/2002 | US20020012665 Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphoma |
| 01/31/2002 | US20020012663 Inhibiting the growth of refractory tumors that are stimulated by a ligand of epidermal growth factor receptor (EGFR) in human patients, comprising treating the human patients with an effective amount of an EGFR/HER1 antagonist |
| 01/31/2002 | US20020012611 Retrieving a selected set of chemical compounds from an addressable chemical storage module with an automated robotic retriever; high throughput chemical screening oflow volume samples for new medicines, agrochemicals, or cosmetics |
| 01/31/2002 | DE10035352A1 Verfahren zur Behandlung von instabiler Angina pectoris A method for the treatment of unstable angina |
| 01/31/2002 | DE10035227A1 Selection and use of lipogenesis inhibitors for the treatment and prevention of obesity |
| 01/31/2002 | DE10035144A1 Cyclische Aminosäurederivate Cyclic amino acid derivatives |
| 01/31/2002 | DE10034802A1 Stabile Salze von O-Acetylsalicylsäure mit basischen Aminosäuren Stable salts of O-acetylsalicylic acid with basic amino acids |
| 01/31/2002 | DE10032456A1 Schnell zerfallende Darreichungsform zur Freisetzung von Wirkstoffen im Mundraum oder in Körperhöhlen Rapidly disintegrating dosage form for the delivery of drugs to the oral cavity or into body cavities |
| 01/31/2002 | CA2797652A1 Multi-component biological transport systems |
| 01/31/2002 | CA2418215A1 Novel fibroblast growth factor (fgf23) and methods for use |
| 01/31/2002 | CA2418204A1 Novel peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 01/31/2002 | CA2418194A1 Tricyclic 2-pyridone compounds useful as hiv reverse transcriptase inhibitors |
| 01/31/2002 | CA2417134A1 Ho-1 suppressor as a diagnostic and prognostic test for dementing diseases |
| 01/31/2002 | CA2417005A1 Regulators of ppar.delta.(.beta.) and their use in the treatment of obesity and insulin resistance |
| 01/31/2002 | CA2416751A1 Alpha v integrin receptor antagonists |
| 01/31/2002 | CA2416691A1 Proteases |
| 01/31/2002 | CA2416657A1 Fh-binding protein of streptococcus pneumoniae |
| 01/31/2002 | CA2416647A1 Method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity |
| 01/31/2002 | CA2416538A1 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| 01/31/2002 | CA2416537A1 Calcilytic compounds |
| 01/31/2002 | CA2416414A1 Human kinases |
| 01/31/2002 | CA2416404A1 Stimulation of cartilage growth with agonists of the non-proteolytically activated thrombin receptor |
| 01/31/2002 | CA2416381A1 Gene-targeted non-human mammal with human fad presenilin mutation and generational offspring |
| 01/31/2002 | CA2416358A1 Use of the interferon receptor 2c polypeptide chain to enhance the anti-growth effects of type i interferons |
| 01/31/2002 | CA2415900A1 Uses for nad synthetase inhibitors |
| 01/31/2002 | CA2415077A1 Cell cycle proteins and mitosis-associated molecules |
| 01/31/2002 | CA2412626A1 Il-17 molecules and uses thereof |
| 01/31/2002 | CA2411192A1 Combination of serotonin agonist (5ht2) and antagonist (5ht6)as a pharmaceutical formulation |
| 01/31/2002 | CA2410766A1 Novel imidazolidinones as ns3-serine protease inhibitors of hepatitis c virus |
| 01/31/2002 | CA2410683A1 Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs |
| 01/31/2002 | CA2410682A1 Novel peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 01/31/2002 | CA2410562A1 Colchinol derivatives as angiogenesis inhibitors |
| 01/31/2002 | CA2354236A1 Use of glycogen phosphorylase inhibitors to inhibit tumor growth |
| 01/30/2002 | EP1176201A2 Platelet-specific chimeric immunoglobulin |
| 01/30/2002 | EP1176140A1 Amide compounds and medicinal use thereof |
| 01/30/2002 | EP1175904A2 Method for inhibiting bone resorption |
| 01/30/2002 | EP1175903A2 Method for inhibiting bone resorption |
| 01/30/2002 | EP1175902A1 Use of CS-866 (olmesartan) in the manufacture of a medicament for treating arteriosclerosis |
| 01/30/2002 | EP1175900A2 Use of growth hormone secretagogues for improvement of fucnctional health status |
| 01/30/2002 | EP1175897A2 Cosmetic or dermatologic formulation to treat and cool the skin after a sun bath |
| 01/30/2002 | EP1175892A1 Use of EP-3 prostaglandins receptor antagonists as cosmetic agent for reducing or stopping hairloss |
| 01/30/2002 | EP1175891A1 Use of non prostanoic agonists of EP-2 and/or EP-2 prostaglandin receptors as cosmetic agent for reducing or stopping hair loss |
| 01/30/2002 | EP1175890A1 Use of E2 (EP-3) prostaglandins receptor agonists for reducing or stopping hairloss in cosmetic compositions |
| 01/30/2002 | EP1175888A2 Topical compositions comprising glycosylated hydroxystilbenes and their uses |
| 01/30/2002 | EP1175513A1 MinK-RELATED GENES, FORMATION OF POTASSIUM CHANNELS AND ASSOCIATION WITH CARDIAC ARRHYTHMIA |